Alzheimer's disease and dementia are neurodegenerative conditions that gradually impair cognitive function and memory. Alzheimer's, the most common form of dementia, typically manifests through progressive memory loss, confusion, and difficulty in reasoning or problem-solving. As these diseases advance, individuals may experience changes in behavior, language difficulties, and even challenges with motor functions.
Recent research focuses on identifying biomarkers—indicators in blood, cerebrospinal fluid, or brain imaging—that could aid in early diagnosis and monitoring of Alzheimer's. These biomarkers include beta-amyloid and tau proteins, which accumulate abnormally in the brains of affected individuals. Advances in biomarker detection offer promise for earlier intervention and more precise tracking of disease progression, potentially leading to improved management strategies and therapeutic developments in the future. Understanding these biomarkers is crucial for developing effective treatments and enhancing the quality of life for those living with Alzheimer's and dementia.
Title : Cerebral vascular calcium signaling in diabetic alzheimer's disease-related dementias
Yong Xiao Wang, Albany Medical College, United States
Title : Deep learning-based risk assessment of cognitive impairment using health examination data
Kaoru Sakatani, The University of Tokyo, Japan
Title : Evaluation of the neuroprotective potential of indicaxanthin from opuntia ficus indica fruit against dysmetabolism-related neurodegeneration both in vivo and in vitro
Mario Allegra, University of Palermo, Italy
Title : Cogs Club: Making a difference
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Development of imaging based biomarkers for neurovascular abnormalities in neurodegenerative diseases
Jun Hua, Johns Hopkins University School of Medicine, United States
Title : Psychosocial considerations in management of corticobasal degeneration
Esraa Askar, Forest Hills Hospital, United States